These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10233493)

  • 1. Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo-controlled study.
    Dinsmore WW; Gingell C; Hackett G; Kell P; Savage D; Oakes R; Frentz GD
    BJU Int; 1999 Feb; 83(3):274-9. PubMed ID: 10233493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phenotolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction.
    Sandhu D; Curless E; Dean J; Hackett G; Liu S; Savage D; Oakes R; Frentz G
    Int J Impot Res; 1999 Apr; 11(2):91-7. PubMed ID: 10356669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasoactive intestinal polypeptide and phentolamine mesylate administered by autoinjector in the treatment of patients with erectile dysfunction resistant to other intracavernosal agents.
    Dinsmore WW; Alderdice DK
    Br J Urol; 1998 Mar; 81(3):437-40. PubMed ID: 9523666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study of the role of intracavernous injection of vasoactive intestinal peptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction.
    McMahon CG
    Int J Impot Res; 1996 Dec; 8(4):233-6. PubMed ID: 8981173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate.
    Shah PJ; Dinsmore W; Oakes RA; Hackett G
    Curr Med Res Opin; 2007 Oct; 23(10):2577-83. PubMed ID: 17875241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents.
    Kiely EA; Bloom SR; Williams G
    Br J Urol; 1989 Aug; 64(2):191-4. PubMed ID: 2765789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction.
    Dinsmore WW; Wyllie MG
    BJU Int; 2008 Sep; 102(8):933-7. PubMed ID: 18485029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure.
    Gerstenberg TC; Metz P; Ottesen B; Fahrenkrug J
    J Urol; 1992 May; 147(5):1277-9. PubMed ID: 1569667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on intracavernosal VIP levels during pharmacologically induced penile erections.
    Kiely EA; Blank MA; Bloom SR; Williams G
    Br J Urol; 1987 Apr; 59(4):334-9. PubMed ID: 2437991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and duplex US assessment of effects of sildenafil on cavernosal arteries of the penis: comparison with intracavernosal injection of vasoactive agents--initial experience.
    Copel L; Katz R; Blachar A; Sosna J; Sheiman RG
    Radiology; 2005 Dec; 237(3):986-91. PubMed ID: 16237136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the synergistic effects of tamsulosin versus phentolamine on penile erection: in vitro and in vivo studies.
    Kim SC; Seo KK; Lee SK; Song ES; Lee MY
    Urol Res; 1999 Dec; 27(6):437-44. PubMed ID: 10651132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group.
    Br J Urol; 1998 Oct; 82(4):538-43. PubMed ID: 9806184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Penile erections induced by vasoactive intestinal peptide and sodium nitroprusside.
    Wang R; Higuera TR; Sikka SC; Minkes RK; Bellan JA; Kadowitz PJ; Domer FR; Hellstrom WJ
    Urol Res; 1993 Jan; 21(1):75-8. PubMed ID: 8456543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Men with mild erectile dysfunction benefit from sildenafil treatment.
    Bénard F; Carrier S; Lee JC; Talwar V; Defoy I
    J Sex Med; 2010 Nov; 7(11):3725-35. PubMed ID: 20946161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intracavernous pharmacotherapy for organic impotence in the elderly].
    Richter S; Shalev M; Nissenkorn I
    Harefuah; 1990 Aug; 119(3-4):66-7. PubMed ID: 2227669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study.
    Shenfeld O; Hanani J; Shalhav A; Vardi Y; Goldwasser B
    J Urol; 1995 Sep; 154(3):1017-9. PubMed ID: 7637045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of oral phentolamine, taken before sleep, on nocturnal erectile activity: a double-blind, placebo-controlled, crossover study.
    Hatzichristou DG; Apostolidis A; Tzortzis V; Hatzimouratidis K; Kouvelas D
    Int J Impot Res; 2001 Oct; 13(5):303-8. PubMed ID: 11890519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An improved vasoactive drug combination for a pharmacological erection program.
    Bennett AH; Carpenter AJ; Barada JH
    J Urol; 1991 Dec; 146(6):1564-5. PubMed ID: 1719248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction.
    Goldstein I; McCullough AR; Jones LA; Hellstrom WJ; Bowden CH; Didonato K; Trask B; Day WW
    J Sex Med; 2012 Apr; 9(4):1122-33. PubMed ID: 22248153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness and safety of cavernous body auto-injection therapy with papaverine/phentolamine. Study group].
    Thon WF; Hartmann U
    Urologe A; 1993 Nov; 32(6):466-9. PubMed ID: 8284856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.